Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohorts

Cancer

Volumn 115, Issue 22, 2009, Pages 5272-5283

  Dignam, James J ^a   Huang, Lan ^b   Ries, Lynn ^b   Reichman, Marsha ^b   Mariotto, Angela ^b   Feuer, Eric ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Cause specific survival; Life tables; Relative survival

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL RESEARCH; CONTROLLED STUDY; DEATH CERTIFICATE; FEMALE; HUMAN; LIFE EXPECTANCY; LYMPH NODE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; CAUSE OF DEATH; CLINICAL TRIALS AS TOPIC; DEATH CERTIFICATES; FEMALE; HUMANS; LIFE EXPECTANCY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POPULATION SURVEILLANCE; REGISTRIES; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 70449449347     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24617     Document Type: Article

References (26)

1. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
2. Henson DE, Ries LA. The relative survival rate. Cancer. 1995;76:1687-1688.
3. Elandt-Johnson R, Johnson NL.Survival Models and Data Analysis. New York, NY: John Wiley & Sons; 1980.
4. Percy C, Stanek E 3rd, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981;71:242-250. (Pubitemid 11146407)
5. Percy CL, Miller BA, Gloeckler Ries LA. Effect of changes in cancer classification and the accuracy of cancer death certificates on trends in cancer mortality. Ann N Y Acad Sci. 1990;609:87-97.
6. Boer R, Ries LA, Ballegooijen M, et al. Ambiguities in calculating cancer patient survival: the SEER experience for colorectal and prostate cancer. Statistical Research and Applications Branch Technical Report No. 2002-2005. Available at: http://srab.cancer.gov/reports. Accessed on July 28, 2009.
7. Miller AB, Yurgalevitch S, Weissfeld JL; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team.Death review process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 suppl):400S-406S.
8. Remington RD. Who should code cause of death in a clinical trial? Control Clin Trials. 1984;5:241-244.
9. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD,Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program 1988-2001, Patient and Tumor Characteristics. NIH Publication No. 07-6215. Bethesda, Md:SEER Program, National Cancer Institute; 2007.
10. Ries LAG, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology and End Results (SEER) Program. Oncologist. 2003;8:541-552.
11. Eaker S, Dickman PW, Hellstrom V, et al. Regional differences in breast cancer survival despite common guidelines. Cancer Epidemiol Biomarkers Prev. 2005;14:2914-2918. (Pubitemid 43068824)
12. Woods LM, Rachet B, Cooper N, Coleman MP. Predicted trends in long-term breast cancer survival in England and Wales. Br J Cancer. 2007;96:1135-1138. (Pubitemid 46608312)
13. National Surgical Adjuvant Breast and Bowel Project (NSABP). NSABP website. Available at: http://www.nsabp.pitt.edu/. Accessed July 28, 2008.
14. Gamel JW, Vogel RL. Nonparametric comparison of relative versus cause-specific survival in Surveillance, Epidemiology and End Results (SEER) programme breast cancer patients. Stat Methods Med Res. 2001;10:339-352.
15. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958;8:699-712.
16. National Center for Health Statistics (NCHS). NCHS website. Available at: http://www.cdc.gov/nchs/. Accessed July 28, 2008.
17. Ernster VL, Barclay J, Kerlikowske K, et al. Mortality among women with ductal carcinoma in situ of the breast in the population-based Surveillance, Epidemiology, and End Results Program. Arch Int Med. 2000;160:953-958.
18. Hakulinen T. On long-term relative survival rates. J Chronic Dis. 1977;30:431-443.
19. Buckley JD. Additive and multiplicative models for relative survival rates. Biometrics. 1984;40:51-62.
20. Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990;9:529-538. (Pubitemid 20235022)
21. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23:51-64.
22. Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in 5 National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24:2028-2037.
23. Anderson SJ, Wapnir IL, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in 5 National Surgical Adjuvant Breast and Bowel Project protocols of node negative breast cancer. J Clin Oncol. 2009;27:2466-2473.
24. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25:2127-2132.
25. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664-8670.
26. Sargent DJ, Patiyil S, Yothers G, et al. for the ACCENT Group.End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007;25:4569-4574.